Aline PRIMOT

Information

Staff scientist

Catherine ANDRÉ Group

+33 (0)2 23 23 32 15

Villejean campus / Building 4 / Room 221/2

Responsibilities

Supervision of junior and graduate students, or visitors

In a few words

My PhD project, “Study of the regulation of 2 kinase proteins: GSK-3 and Polo.”, was structured around 2 protein families, the "Glycogen Synthase Kinase-3" (GSK-3eta) and Polo, involved, respectively, in the regulation of the Wnt pathway and the control of the cell cycle. I realized my PhD in the Dr L. Meijer’s team at the Biological station of Roscoff (Finistère, France).

 

In 2002, I joined the Dr MD. Galibert’s team (“Gene expression and oncogenesis”) for a post-doctorate on different projects structured around the study of the UV response and melanoma:

  • Functional analyse of the Microphtalmia gene transcripts and their implications in the acquisition of a cancer phenotype: melanoma.
  • UV-dependant regulation of pigmentation genes expression.
  • Evaluation of lichen molecules on the pigmentation.

 

My second post doctoral project (2008-2009) is a continuation of the study of melanoma. It was conducted within the "canine genetics" team and focused on the analysis of target genes mutations, whose involvement in the development of melanomas in humans has been demonstrated, in samples of canine melanoma .

 

From April 2009 to September 2014, I was study director within C.RIS Pharma in Saint Malo, headed by Dr. Pierrick Auvray. The CRO ("Contract Resarch Organization") specializes in the in vitro and in vivo preclinical development of new molecules according to Good Laboratory Practices (GLP) and in accordance with ISO 9001.

 

Since October 2014, I work in the "canine genetics" team on the study of non UV-dependent melanoma (mucosal and uveal) in dogs. The aim of this project is to study somatic and predisposing mutations in gene responsible for the cancerisation of oral and uveal (iris, ciliary body and choroid) melanocytes in dogs. The most relevant mutated genes will be validated with functional analysis to develop an animal model for the study of new therapeutic targets and transfer this data to humans.

 

 

Major publications

  • Gillard M, Cadieu E, De Brito C, Abadie J, Vergier B, Devauchelle P, Degorce F, Dréano S, Primot A, Dorso L, Lagadic M, Galibert F, Hédan B, Galibert MD, André C. Naturally occurring melanomas in dogs as models for non-UV pathways of human melanomas. Pigment Cell Melanoma Res. 2014 Jan; 27(1):90-102.


    Primot A, Mogha A, Corre S, Roberts K, Debbache J, Adamski H, Dreno B, Khammari A, Lesimple T, Mereau A, Goding CR, Galibert MD. ERK-regulated differential expression of the Mitf 6a/b splicing isoforms in melanoma. Pigment Cell Melanoma Res. 2010 Feb; 23(1):93-102.


    Méreau A, Anquetil V, Cibois M, Noiret M, Primot A, Vallée A, Paillard L.  Analysis of splicing patterns by pyrosequencing. Nucleic Acids Res. 2009 Oct; 37(19).


    Corre S, Primot A, Baron Y, Le Seyec J, Goding C, Galibert MD. Target gene specificity of USF-1 is directed via p38-mediated phosphorylation-dependent acetylation. J Biol Chem. 2009 Jul 10; 284(28):18851-62.


    Corre S, Primot A, Sviderskaya E, Bennett DC, Vaulont S, Goding CR, Galibert MD. UV-induced expression of key component of the tanning process, the POMC and MC1R genes, is dependent on the p-38-activated upstream stimulating factor-1 (USF-1). J Biol Chem. 2004 Dec 3; 279(49):51226-33.


    Droucheau E, Primot A, Thomas V, Mattei D, Knockaert M, Richardson C, Sallicandro P, Alano P, Jafarshad A, Baratte B, Kunick C, Parzy D, Pearl L, Doerig C, Meijer L. Plasmodium falciparum glycogen synthase kinase-3: molecular model, expression, intracellular localisation and selective inhibitors. Biochim Biophys Acta. 2004 Mar 11; 1697(1-2):181-96. Review. Erratum in: Biochim Biophys Acta. 2004 Jul 1; 1700(1):139-40.


    Primot A, Baratte B, Gompel M, Borgne A, Liabeuf S, Romette JL, Jho EH, Costantini F, Meijer L. Purification of GSK-3 by affinity chromatography on immobilized axin. Protein Expr Purif. 2000 Dec; 20(3):394-404.

     

Subscribe to our newsletter